Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations

BACKGROUND: Robenacoxib is a non-steroidal anti-inflammatory drug available for canine and feline use for the control of pain and inflammation marketed as Onsior™. The aim of this target animal safety study was to evaluate the 6-month safety profile of oral robenacoxib administration. It was a rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Toutain, Céline E., Brossard, Patrick, King, Stephen B., Helbig, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098579/
https://www.ncbi.nlm.nih.gov/pubmed/30119677
http://dx.doi.org/10.1186/s12917-018-1566-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098579/
https://www.ncbi.nlm.nih.gov/pubmed/30119677
http://dx.doi.org/10.1186/s12917-018-1566-1

Ejemplares similares